Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2005

Open Access 01-12-2005 | Review

Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy

Author: Christine V Ichim

Published in: Journal of Translational Medicine | Issue 1/2005

Login to get access

Abstract

Experimental and clinical experience demonstrates that the resolution of a pathogenic challenge depends not only on the presence or absence of an immune reaction, but also on the initiation of the proper type of immune reaction. The initiation of a non-protective type of immune reaction will not only result in a lack of protection, but may also exacerbate the underlying condition. For example, in cancer, constituents of the immune system have been shown to augment tumor proliferation, angiogenesis, and metastases. This review discusses the duality of the role of the immune system in cancer, from the theories of immunosurveillance and immunostimulation to current studies, which illustrate that the immune system has both a protective role and a tumor-promoting role in neoplasia. The potential of using chemotherapy to inhibit a tumor-promoting immune reaction is also discussed.
Literature
1.
2.
Wiemann B, Starnes CO: Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994, 64 (3): 529-64.PubMed
3.
Modlin RL: Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol. 1994, 102 (6): 828-32.PubMed
4.
Ehrlich P: The collected papers of Paul Ehrlich. Edited by: Himmelweit F. 1957, London: Pergamon Press, II:
5.
Thomas L: Cellular and Humoral Aspects of Hypersensitivity. Edited by: Lawrence HS. 1959, New York: Hoeber-Harper
6.
7.
Sugiyama T, Yoshida TO, Nishizuka Y: Immunosuppression after single and multiple pulse doses of 7,12-dimethylbenz(a)anthracene in the rat. Gann. 1973, 64 (4): 397-400.PubMed
8.
Lappe MA, Steinmuller DS: Depression of weak allograft immunity in the mouse by neonatal or adult exposure to urethan. Cancer Res. 1970, 30 (3): 674-8.PubMed
9.
Ball JK, Sinclair NR, McCarter JA: Prolonged immunosuppression and tumor induction by a chemical carcinogen injected at birth. Science. 1966, 152: 650-651.PubMed
10.
Outzen HC: Spontaneous and induced tumor incidence in germfree "nude" mice. J Reticuloendothel Soc. 1975, 17 (1): 1-9.PubMed
11.
Penn I: Tumors of the immunocompromised patient. Annu Rev Med. 1988, 39: 63-73.PubMed
12.
Stewart T: Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995, 346 (8978): 796-8.PubMed
13.
Melief CJM, Schwartz MA: Immunocompetence and malignancy, in Cancer: A comprehensive treatise. Edited by: Beckman F. 1975, Plenum Press: New York, 121-159.
14.
Stutman O: Immunodepression and malignancy. Adv Cancer Res. 1975, 22: 261-422.PubMed
15.
Prehn RT: Relationship of tumor immunogenicity to concentration of the oncogen. J Natl Cancer Inst. 1975, 55 (1): 189-90.PubMed
16.
Lawler EM, Prehn RT: Influence of immune status of host on immunogenicity of tumors induced with two doses of methylcholanthrene. Cancer Immunol Immunother. 1982, 13 (3): 194-7.PubMed
17.
Carbone G: Activation of ras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas. Int J Cancer. 1991, 47 (4): 619-25.PubMed
18.
Marchant J: Sarcoma induction in mice by methylcholanthrene. Antigenicity tests of sarcomas induced in thymus grafted and control animals. Br J Cancer. 1969, 23 (2): 383-90.PubMedCentralPubMed
19.
Mitchell GF, Rajasekariah GR, Rickard MD: A mechanism to account for mouse strain variation in resistance to the larval cestode, Taenia taeniaeformis. Immunology. 1980, 39 (4): 481-9.PubMedCentralPubMed
20.
Nicchitta CV: Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat Rev Immunol. 2003, 3 (5): 427-32.PubMed
21.
Birkeland SA: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995, 60 (2): 183-9.PubMed
22.
Pham SM: Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg. 1995, 60 (6): 1623-6.PubMed
23.
Haliotis T: Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. Int J Cancer. 1985, 35 (4): 505-13.PubMed
24.
Gallo-Hendrikx E: Enhancement of pancreatic tumor metastasis in transgenic immunodeficient mice. Oncogene. 1994, 9 (10): 2983-90.PubMed
25.
Gorelik E: Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer. 1982, 30 (1): 107-12.PubMed
26.
Harning R, Koo GC, Szalay J: Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest Ophthalmol Vis Sci. 1989, 30 (9): 1909-15.PubMed
27.
Talmadge JE: Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J Natl Cancer Inst. 1980, 65 (5): 929-35.PubMed
28.
Talmadge JE: Role of NK cells in tumour growth and metastasis in beige mice. Nature. 1980, 284 (5757): 622-4.PubMed
29.
Kobayashi N: Malignant neoplasms in registered cases of primary immunodeficiency syndrome. Jpn J Clin Oncol. 1985, 15 (Suppl 1): 307-12.PubMed
30.
Kumazawa H: Suppression of natural killer cell activity by serum derived from head and neck cancer patients. Cancer Detect Prev. 1995, 19 (6): 494-502.PubMed
31.
Holmes E, Sibbitt WL, Bankhurst AD: Serum factors which suppress natural cytotoxicity in cancer patients. Int Arch Allergy Appl Immunol. 1986, 80 (1): 39-43.PubMed
32.
Bugis SP: Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother. 1990, 31 (3): 176-81.PubMed
33.
Campos MM: Clinical implications of natural killer cytotoxicity in patients with squamous cell carcinoma of the penis. Nat Immun. 1998, 16 (5–6): 256-62.PubMed
34.
Aparicio-Pages NM: Impaired local natural killer cell activity in human colorectal carcinomas. Cancer Immunol Immunother. 1989, 28 (4): 301-4.PubMed
35.
Chuang WL, Liu HW, Chang WY: Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer. 1990, 65 (4): 926-30.PubMed
36.
Funa K: Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas. Br J Cancer. 1984, 50 (2): 231-3.PubMedCentralPubMed
37.
Introna M: Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ. J Natl Cancer Inst. 1983, 70 (1): 21-6.PubMed
38.
Morita T, Tokue A, Minato N: Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer. Cancer Immunol Immunother. 1990, 32 (3): 191-4.PubMed
39.
Gonzalez FM: Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1998, 124 (8): 852-6.PubMed
40.
Taketomi A: Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer. 1998, 83 (1): 58-63.PubMed
41.
Tajima F: Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia. 1996, 10 (3): 478-82.PubMed
42.
Nakamura H: Cellular immunologic parameters related to age, gender, and stage in lung cancer patients. Lung Cancer. 2000, 28 (2): 139-45.PubMed
43.
Liljefors M: Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer. 2003, 105 (5): 717-23.PubMed
44.
Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood. 1992, 79 (12): 3101-9.PubMed
45.
Miller JS: The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001, 29 (10): 1157-68.PubMed
46.
Loza MJ, Perussia B: Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation?. Nat Immunol. 2001, 2 (10): 917-24.PubMed
47.
Smyth MJ: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002, 2 (11): 850-61.PubMed
48.
Lyerly HK: Quantitating cellular immune responses to cancer vaccines. Semin Oncol. 2003, 30 (3 Suppl 8): 9-16. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer.PubMed
49.
Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004, 21 (2): 137-48.PubMed
50.
Cui Z, Willingham MC: The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunol Immunother. 2004, 53 (6): 473-8. Epub 2004 Jan 17. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer.PubMed
51.
Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science. 2004, 305 (5681): 200-5.PubMed
52.
Nakamura E: Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res. 2002, 8 (8): 2620-5.PubMed
53.
Wittke F: Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer. 1999, 79 (7–8): 1182-4.PubMedCentralPubMed
54.
Elsasser-Beile U: Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol. 1998, 19 (6): 470-6.PubMed
55.
Lauerova L: Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma. 2002, 49 (3): 159-66.PubMed
56.
Mori T: T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother. 2001, 50 (10): 566-8.PubMed
57.
De Vita F: Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep. 2000, 7 (2): 357-61.PubMed
58.
Mocellin S, Wang E, Marincola FM: Cytokines and immune response in the tumor microenvironment. J Immunother. 2001, 24 (5): 392-407.
59.
Mocellin S: The dual role of IL-10. Trends Immunol. 2003, 24 (1): 36-43.PubMed
60.
Kundu N, Fulton AM: Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol. 1997, 180 (1): 55-61.PubMed
61.
Kundu N: Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer. 1998, 76 (5): 713-9.PubMed
62.
Dorsey R: Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res. 2002, 62 (9): 2606-10.PubMed
63.
Mocellin S: Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer. 2001, 93 (2): 236-42.PubMed
64.
Kammula US, Marincola FM, Rosenberg SA: Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst. 2000, 92 (16): 1336-44.PubMed
65.
Zanussi S: Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother. 2003, 52 (1): 28-32.PubMed
66.
Sato M: Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res. 1998, 18 (5D): 3951-5.PubMed
67.
Nowell PC: The clonal evolution of tumor cell populations. Science. 1976, 194 (4260): 23-8.PubMed
68.
Dighe AS: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994, 1 (6): 447-56.PubMed
69.
Shankaran V: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410 (6832): 1107-11.PubMed
70.
Kaplan DH: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998, 95 (13): 7556-61.PubMedCentralPubMed
71.
Street SE, Cretney E, Smyth MJ: Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001, 97 (1): 192-7.PubMed
72.
Street SE: Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002, 196 (1): 129-34.PubMedCentralPubMed
73.
Kominsky S: IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 1998, 17 (23): 2973-9.PubMed
74.
Hobeika AC: IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res. 1999, 19 (12): 1351-61.PubMed
75.
Kominsky SL: Inhibitory effects of IFN-gamma and acyclovir on the glioblastoma cell cycle. J Interferon Cytokine Res. 2000, 20 (5): 463-9.PubMed
76.
Chin YE: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996, 272 (5262): 719-22.PubMed
77.
Mandal M: Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene. 1998, 16 (2): 217-25.PubMed
78.
Wall L: IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res. 2003, 9 (7): 2487-96.PubMed
79.
Detjen KM: Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int J Oncol. 2002, 21 (5): 1133-40.PubMed
80.
Detjen KM: Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001, 49 (2): 251-62.PubMedCentralPubMed
81.
Xu X: IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998, 58 (13): 2832-7.PubMed
82.
Luster AD, Ravetch JV: Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med. 1987, 166 (4): 1084-97.PubMed
83.
84.
Farber JM: A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci U S A. 1990, 87 (14): 5238-42.PubMedCentralPubMed
85.
Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13 (2): 95-109.PubMed
86.
Flexner S, Jobling JW: Proc Soc Exp Biol Med. 1907, 4: 461-
87.
Clerici M, Clerici E, Shearer GM: The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst. 1996, 88 (7): 461-2.PubMed
88.
Mosmann TR: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986, 136 (7): 2348-57.PubMed
89.
Kaliss N: Immunological enhancement of tumor homografts in mice: a review. Cancer Res. 1958, 18 (9): 992-1003.PubMed
90.
Prehn RT: The immune reaction as a stimulator of tumor growth. Science. 1972, 176 (31): 170-1.PubMed
91.
Prehn RT: Immunostimulation of chemical oncogenesis in the mouse. Int J Cancer. 1977, 20 (6): 918-22.PubMed
92.
Outzen HC: Development of carcinogen-induced skin tumors in mice with varied states of immune capacity. Int J Cancer. 1980, 26 (1): 87-92.PubMed
93.
Outzen HC: A preliminary analysis of skin tumor induction in immunomodulated mice, in Proceedings of the symposium on the use of athymic nude mice in cancer research. Edited by: Overjera A. 1978, Gustav Fisher: New York, 93-99.
94.
Chai CK: Hyperplastic growth in skin grafts of rabbits. J Hered. 1982, 73 (4): 304-PubMed
95.
Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315 (26): 1650-9.PubMed
96.
Ehrlich P: Beitrage zur Kenntniss der granulierten bindegenwebszellen und der eosinophilen leukocyten. Archiv fur Anatomie und Physiologie (Leipzig). 1879, 3: 166-169.
97.
Fisher ER: Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol. 1989, 20 (2): 159-63.PubMed
98.
Imada A: Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J. 2000, 15 (6): 1087-93.PubMed
99.
Tomita M, Matsuzaki Y, Onitsuka T: Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg. 2000, 69 (6): 1686-90.PubMed
100.
Erkilic S, Erbagci Z: The significance of mast cells associated with basal cell carcinoma. J Dermatol. 2001, 28 (6): 312-5.PubMed
101.
Ninck S: Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer. 2003, 106 (1): 34-44.PubMed
102.
Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med. 1980, 303 (15): 878-80.PubMed
103.
Giri D, Ropiquet F, Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999, 5 (5): 1063-71.PubMed
104.
Takahashi JA: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg. 1992, 76 (5): 792-8.PubMed
105.
Turner AM: Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood. 1992, 80 (2): 374-81.PubMed
106.
Roche WR: The nature and significance of tumour-associated mast cells. J Pathol. 1986, 148 (2): 175-82.PubMed
107.
Starkey JR, Crowle PK, Taubenberger S: Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer. 1988, 42 (1): 48-52.PubMed
108.
Zhang W: Modulation of tumor angiogenesis by stem cell factor. Cancer Res. 2000, 60 (23): 6757-62.PubMed
109.
Ionov ID: Inhibition of mast cell activity as a new approach to anti-cancer therapy. Int J Radiat Biol. 1991, 60 (1–2): 287-91.PubMed
110.
Ribatti D: Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane. Clin Exp Allergy. 2001, 31 (4): 602-8.PubMed
111.
Gibbs BF: Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol. 2001, 10 (5): 312-20.PubMed
112.
Qu Z: Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol. 1995, 147 (3): 564-73.PubMedCentralPubMed
113.
Fan L, Iseki S: Immunohistochemical localization of vascular endothelial growth factor in the globule leukocyte/mucosal mast cell of the rat respiratory and digestive tracts. Histochem Cell Biol. 1999, 111 (1): 13-21.PubMed
114.
Yamada T: Localization of vascular endothelial growth factor in synovial membrane mast cells: examination with "multi-labelling subtraction immunostaining". Virchows Arch. 1998, 433 (6): 567-70.PubMed
115.
Vartio T, Seppa H, Vaheri A: Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J Biol Chem. 1981, 256 (1): 471-7.PubMed
116.
Lees M, Taylor DJ, Woolley DE: Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem. 1994, 223 (1): 171-7.PubMed
117.
Marks RM: Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest. 1986, 55 (3): 289-94.PubMed
118.
Galli SJ: Mast cells: immunologically specific effectors and potential sources of multiple cytokines during IgE-dependent responses. Ciba Found Symp. 1989, 147: 53-65.PubMed
119.
Burd PR: Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med. 1989, 170 (1): 245-57.PubMed
120.
Smith TJ, Parikh SJ: HMC-1 mast cells activate human orbital fibroblasts in coculture: evidence for up-regulation of prostaglandin E2 and hyaluronan synthesis. Endocrinology. 1999, 140 (8): 3518-25.PubMed
121.
Frungieri MB: Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma : Possible relevance to human fibrotic disorders. Proc Natl Acad Sci U S A. 2002, 99 (23): 15072-7.PubMedCentralPubMed
122.
Tetlow LC: Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis. 1998, 57 (1): 25-32.PubMedCentralPubMed
123.
Khoo NK: Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis. 1992, 10 (4): 239-52.PubMed
124.
Yunker VM, Taraskina NP, Ustinov AS: Participation of macrophages in the mechanism mediating the enhancement of metastasis formation after tumour resection. Biomed Sci. 1991, 2 (6): 569-75.PubMed
125.
Fulton AM: Inhibition of experimental metastasis with indomethacin: role of macrophages and natural killer cells. Prostaglandins. 1988, 35 (3): 413-25.PubMed
126.
Tang R: M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes?. J Cell Biochem. 1992, 50 (4): 350-6.PubMed
127.
Lewis JS: Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000, 192 (2): 150-8.PubMed
128.
Leek RD: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56 (20): 4625-9.PubMed
129.
Salvesen HB, Akslen LA: Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer. 1999, 84 (5): 538-43.PubMed
130.
Hanada T: Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000, 7 (7): 263-9.PubMed
131.
Shimura S: Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000, 60 (20): 5857-61.PubMed
132.
Lissbrant IF: Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol. 2000, 17 (3): 445-51.PubMed
133.
Koukourakis MI: Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer. 1998, 77 (10): 1696-703.PubMedCentralPubMed
134.
Toomey D: Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer. 2003, 103 (3): 408-12.PubMed
135.
Nishie A: Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999, 5 (5): 1107-13.PubMed
136.
Rossi ML: The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol. 1989, 78 (2): 189-93.PubMed
137.
Mantovani A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23 (11): 549-55.PubMed
138.
Kerkela E: Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol. 2002, 198 (2): 258-69.PubMed
139.
Cornelius LA: Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998, 161 (12): 6845-52.PubMed
140.
Dell'Eva R: Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy. Endothelium. 2002, 9 (1): 3-10.PubMed
141.
Denis M, Ghadirian E: Human monocyte tumouristatic ability: modulation by cytokines and tumour cell products. Int J Immunopharmacol. 1990, 12 (5): 509-13.PubMed
142.
Kambayashi T: Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol. 1995, 154 (7): 3383-90.PubMed
143.
Maeda H: TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol. 1995, 155 (10): 4926-32.PubMed
144.
Beissert S: Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci U S A. 1989, 86 (13): 5064-8.PubMedCentralPubMed
145.
Dinapoli MR, Calderon CL, Lopez DM: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med. 1996, 183 (4): 1323-9.PubMed
146.
Lin EY: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001, 193 (6): 727-40.PubMedCentralPubMed
147.
Nowicki A: Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer. 1996, 65 (1): 112-9.PubMed
148.
Leek RD: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999, 79 (5–6): 991-5.PubMedCentralPubMed
149.
Onita T: Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res. 2002, 8 (2): 471-80.PubMed
150.
Turner L: Hypoxia inhibits macrophage migration. Eur J Immunol. 1999, 29 (7): 2280-7.PubMed
151.
Burke B: Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol. 2002, 196 (2): 204-12.PubMed
152.
Harmey JH: Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998, 5 (3): 271-8.PubMed
153.
Negus RP: Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol. 1998, 63 (6): 758-65.PubMed
154.
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9 (6): 669-76.PubMed
155.
Hildenbrand R: Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol. 1999, 66 (1): 40-9.PubMed
156.
Davies B: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993, 53 (22): 5365-9.PubMed
157.
Sica A: Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 2000, 164 (2): 762-7.PubMed
158.
Groux H: Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996, 184 (1): 19-29.PubMed
159.
Scotton CJ: Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res. 2001, 61 (13): 4961-5.PubMed
160.
Wang JM: Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkappaB activation. Int J Cancer. 1998, 75 (6): 900-7.PubMed
161.
Azenshtein E: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002, 62 (4): 1093-102.PubMed
162.
Richmond A, Thomas HG: Purification of melanoma growth stimulatory activity. J Cell Physiol. 1986, 129 (3): 375-84.PubMed
163.
Olbina G: Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides. Anticancer Res. 1996, 16 (6B): 3525-30.PubMed
164.
Galffy G: Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 1999, 59 (2): 367-71.PubMed
165.
Xu L, Fidler IJ: Interleukin 8 an autocrine growth factor for human ovarian cancer. Oncol Res. 2000, 12 (2): 97-106.PubMed
166.
Takamori H: Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas. 2000, 21 (1): 52-6.PubMed
167.
Richards BL: Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg. 1997, 174 (5): 507-12.PubMed
168.
Strieter RM: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995, 270 (45): 27348-57.PubMed
169.
Keane MP: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997, 159 (3): 1437-43.PubMed
170.
Arenberg DA: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996, 184 (3): 981-92.PubMed
171.
Voest EE: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995, 87 (8): 581-6.PubMed
172.
Sgadari C, Angiolillo AL, Tosato G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996, 87 (9): 3877-82.PubMed
173.
Kanegane C: Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol. 1998, 64 (3): 384-92.PubMed
174.
Wang JM: Chemokines and their role in tumor growth and metastasis. J Immunol Methods. 1998, 220 (1–2): 1-17.PubMed
175.
Youngs SJ: Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer. 1997, 71 (2): 257-66.PubMed
176.
Wakabayashi H, Cavanaugh PG, Nicolson GL: Purification and identification of mouse lung microvessel endothelial cell-derived chemoattractant for lung-metastasizing murine RAW117 large-cell lymphoma cells: identification as mouse monocyte chemotactic protein 1. Cancer Res. 1995, 55 (19): 4458-64.PubMed
177.
Muller A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410 (6824): 50-6.PubMed
178.
Bilenker JH, Haller DG: Future directions with angiogenesis inhibitors in colorectal cancer. Clin Colorectal Cancer. 2004, 4 (Suppl 2): S86-93.PubMed
179.
Gabrilovich DI: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999, 5 (10): 2963-70.PubMed
180.
Gabrilovich D: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998, 92 (11): 4150-66.PubMed
181.
Ohm JE: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003, 101 (12): 4878-86. Epub 2003 Feb 13PubMed
182.
Khan NA: Inhibition of diabetes in NOD mice by human pregnancy factor. Hum Immunol. 2001, 62 (12): 1315-23.PubMed
183.
Triozzi PL, Stevens VC: Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep. 1999, 6 (1): 7-17.PubMed
184.
Tani T: Blood purification therapy in cancer treatment. Ther Apher. 1998, 2 (3): 182-4.PubMed
185.
Lentz MR: Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Mod. 1989, 8 (5): 511-27.PubMed
186.
Lentz MR: The role of therapeutic apheresis in the treatment of cancer: a review. Ther Apher. 1999, 3 (1): 40-9.PubMed
187.
Tullis RH: Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purif. 2003, 21 (1): 58-63.PubMed
188.
Hill JA: Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol. 2003, 171 (2): 691-6.PubMed
189.
Liu G: Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur J Immunol. 2004, 34 (6): 1680-7.PubMed
190.
Kim TW: Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 2005, 65 (1): 309-16.PubMed
191.
Li M: Induction of RNA interference in dendritic cells. Immunol Res. 2004, 30 (2): 215-30.PubMed
192.
Urban-Klein B: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004, 23: 23-.
193.
Dunn GP: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002, 3 (11): 991-8.PubMed
194.
Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004, 4 (1): 11-22.PubMed
195.
Prehn RT, Prehn LM: The flip side of tumor immunity. Arch Surg. 1989, 124 (1): 102-6.PubMed
Metadata
Title
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy
Author
Christine V Ichim
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2005
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-3-8

Other articles of this Issue 1/2005

Journal of Translational Medicine 1/2005 Go to the issue

Methodology

Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working on a differential diagnosis in a single case

Commentary

Progress and controversies in developing cancer vaccines

Research

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Research

In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines

Review

RNA amplification for successful gene profiling analysis

Research

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits